世界のペプチドバイオシミラー市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Peptides Biosimilars Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4503
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、99ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、ペプチドバイオシミラーのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（グルカゴン、カルシトニン）、用途別市場規模（腫瘍、慢性疾患、自己免疫疾患、血液疾患、成長ホルモン欠乏症、感染症、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・ペプチドバイオシミラーの市場動向
・企業の競争状況、市場シェア
・ペプチドバイオシミラーの種類別市場規模（グルカゴン、カルシトニン）
・ペプチドバイオシミラーの用途別市場規模（腫瘍、慢性疾患、自己免疫疾患、血液疾患、成長ホルモン欠乏症、感染症、その他）
・ペプチドバイオシミラーの北米市場規模2016-2027（アメリカ、カナダ）
・ペプチドバイオシミラーのヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・ペプチドバイオシミラーのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・ペプチドバイオシミラーの中南米市場規模2016-2027（メキシコ、ブラジル）
・ペプチドバイオシミラーの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Sandoz、Pfizer、Teva Pahrmaceutical、Celltrion、Biocon、Amgen、Samsung Biologics、Mylan、Dr. Reddy's Laboratories、Stada Arzneimittel AG）
・結論

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. The statistic scope in this report is peptides biosimilars.

Market Analysis and Insights: Global Peptides Biosimilars Market
The global Peptides Biosimilars market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Peptides Biosimilars market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Peptides Biosimilars market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Peptides Biosimilars market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Peptides Biosimilars market.

Global Peptides Biosimilars Scope and Market Size
Peptides Biosimilars market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Peptides Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Glucagon
Calcitonin

Segment by Application
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Other Diseases

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Sandoz
Pfizer
Teva Pahrmaceutical
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy’s Laboratories

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptides Biosimilars Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Glucagon
1.2.3 Calcitonin
1.3 Market by Application
1.3.1 Global Peptides Biosimilars Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Oncology
1.3.3 Chronic Diseases
1.3.4 Autoimmune Diseases
1.3.5 Blood Disorders
1.3.6 Growth Hormone Deficiency
1.3.7 Infectious Diseases
1.3.8 Other Diseases
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Peptides Biosimilars Market Perspective (2016-2027)
2.2 Peptides Biosimilars Growth Trends by Regions
2.2.1 Peptides Biosimilars Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Peptides Biosimilars Historic Market Share by Regions (2016-2021)
2.2.3 Peptides Biosimilars Forecasted Market Size by Regions (2022-2027)
2.3 Peptides Biosimilars Industry Dynamic
2.3.1 Peptides Biosimilars Market Trends
2.3.2 Peptides Biosimilars Market Drivers
2.3.3 Peptides Biosimilars Market Challenges
2.3.4 Peptides Biosimilars Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Peptides Biosimilars Players by Revenue
3.1.1 Global Top Peptides Biosimilars Players by Revenue (2016-2021)
3.1.2 Global Peptides Biosimilars Revenue Market Share by Players (2016-2021)
3.2 Global Peptides Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Peptides Biosimilars Revenue
3.4 Global Peptides Biosimilars Market Concentration Ratio
3.4.1 Global Peptides Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptides Biosimilars Revenue in 2020
3.5 Peptides Biosimilars Key Players Head office and Area Served
3.6 Key Players Peptides Biosimilars Product Solution and Service
3.7 Date of Enter into Peptides Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Peptides Biosimilars Breakdown Data by Type
4.1 Global Peptides Biosimilars Historic Market Size by Type (2016-2021)
4.2 Global Peptides Biosimilars Forecasted Market Size by Type (2022-2027)

5 Peptides Biosimilars Breakdown Data by Application
5.1 Global Peptides Biosimilars Historic Market Size by Application (2016-2021)
5.2 Global Peptides Biosimilars Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Peptides Biosimilars Market Size (2016-2027)
6.2 North America Peptides Biosimilars Market Size by Type
6.2.1 North America Peptides Biosimilars Market Size by Type (2016-2021)
6.2.2 North America Peptides Biosimilars Market Size by Type (2022-2027)
6.2.3 North America Peptides Biosimilars Market Size by Type (2016-2027)
6.3 North America Peptides Biosimilars Market Size by Application
6.3.1 North America Peptides Biosimilars Market Size by Application (2016-2021)
6.3.2 North America Peptides Biosimilars Market Size by Application (2022-2027)
6.3.3 North America Peptides Biosimilars Market Size by Application (2016-2027)
6.4 North America Peptides Biosimilars Market Size by Country
6.4.1 North America Peptides Biosimilars Market Size by Country (2016-2021)
6.4.2 North America Peptides Biosimilars Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Peptides Biosimilars Market Size (2016-2027)
7.2 Europe Peptides Biosimilars Market Size by Type
7.2.1 Europe Peptides Biosimilars Market Size by Type (2016-2021)
7.2.2 Europe Peptides Biosimilars Market Size by Type (2022-2027)
7.2.3 Europe Peptides Biosimilars Market Size by Type (2016-2027)
7.3 Europe Peptides Biosimilars Market Size by Application
7.3.1 Europe Peptides Biosimilars Market Size by Application (2016-2021)
7.3.2 Europe Peptides Biosimilars Market Size by Application (2022-2027)
7.3.3 Europe Peptides Biosimilars Market Size by Application (2016-2027)
7.4 Europe Peptides Biosimilars Market Size by Country
7.4.1 Europe Peptides Biosimilars Market Size by Country (2016-2021)
7.4.2 Europe Peptides Biosimilars Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Peptides Biosimilars Market Size (2016-2027)
8.2 Asia-Pacific Peptides Biosimilars Market Size by Type
8.2.1 Asia-Pacific Peptides Biosimilars Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Peptides Biosimilars Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Peptides Biosimilars Market Size by Type (2016-2027)
8.3 Asia-Pacific Peptides Biosimilars Market Size by Application
8.3.1 Asia-Pacific Peptides Biosimilars Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Peptides Biosimilars Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Peptides Biosimilars Market Size by Application (2016-2027)
8.4 Asia-Pacific Peptides Biosimilars Market Size by Region
8.4.1 Asia-Pacific Peptides Biosimilars Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Peptides Biosimilars Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Peptides Biosimilars Market Size (2016-2027)
9.2 Latin America Peptides Biosimilars Market Size by Type
9.2.1 Latin America Peptides Biosimilars Market Size by Type (2016-2021)
9.2.2 Latin America Peptides Biosimilars Market Size by Type (2022-2027)
9.2.3 Latin America Peptides Biosimilars Market Size by Type (2016-2027)
9.3 Latin America Peptides Biosimilars Market Size by Application
9.3.1 Latin America Peptides Biosimilars Market Size by Application (2016-2021)
9.3.2 Latin America Peptides Biosimilars Market Size by Application (2022-2027)
9.3.3 Latin America Peptides Biosimilars Market Size by Application (2016-2027)
9.4 Latin America Peptides Biosimilars Market Size by Country
9.4.1 Latin America Peptides Biosimilars Market Size by Country (2016-2021)
9.4.2 Latin America Peptides Biosimilars Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Peptides Biosimilars Market Size (2016-2027)
10.2 Middle East & Africa Peptides Biosimilars Market Size by Type
10.2.1 Middle East & Africa Peptides Biosimilars Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Peptides Biosimilars Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Peptides Biosimilars Market Size by Type (2016-2027)
10.3 Middle East & Africa Peptides Biosimilars Market Size by Application
10.3.1 Middle East & Africa Peptides Biosimilars Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Peptides Biosimilars Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Peptides Biosimilars Market Size by Application (2016-2027)
10.4 Middle East & Africa Peptides Biosimilars Market Size by Country
10.4.1 Middle East & Africa Peptides Biosimilars Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Peptides Biosimilars Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Sandoz
11.1.1 Sandoz Company Details
11.1.2 Sandoz Business Overview
11.1.3 Sandoz Peptides Biosimilars Introduction
11.1.4 Sandoz Revenue in Peptides Biosimilars Business (2016-2021)
11.1.5 Sandoz Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Peptides Biosimilars Introduction
11.2.4 Pfizer Revenue in Peptides Biosimilars Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Teva Pahrmaceutical
11.3.1 Teva Pahrmaceutical Company Details
11.3.2 Teva Pahrmaceutical Business Overview
11.3.3 Teva Pahrmaceutical Peptides Biosimilars Introduction
11.3.4 Teva Pahrmaceutical Revenue in Peptides Biosimilars Business (2016-2021)
11.3.5 Teva Pahrmaceutical Recent Development
11.4 Celltrion
11.4.1 Celltrion Company Details
11.4.2 Celltrion Business Overview
11.4.3 Celltrion Peptides Biosimilars Introduction
11.4.4 Celltrion Revenue in Peptides Biosimilars Business (2016-2021)
11.4.5 Celltrion Recent Development
11.5 Biocon
11.5.1 Biocon Company Details
11.5.2 Biocon Business Overview
11.5.3 Biocon Peptides Biosimilars Introduction
11.5.4 Biocon Revenue in Peptides Biosimilars Business (2016-2021)
11.5.5 Biocon Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Peptides Biosimilars Introduction
11.6.4 Amgen Revenue in Peptides Biosimilars Business (2016-2021)
11.6.5 Amgen Recent Development
11.7 Samsung Biologics
11.7.1 Samsung Biologics Company Details
11.7.2 Samsung Biologics Business Overview
11.7.3 Samsung Biologics Peptides Biosimilars Introduction
11.7.4 Samsung Biologics Revenue in Peptides Biosimilars Business (2016-2021)
11.7.5 Samsung Biologics Recent Development
11.8 Mylan
11.8.1 Mylan Company Details
11.8.2 Mylan Business Overview
11.8.3 Mylan Peptides Biosimilars Introduction
11.8.4 Mylan Revenue in Peptides Biosimilars Business (2016-2021)
11.8.5 Mylan Recent Development
11.9 Dr. Reddy’s Laboratories
11.9.1 Dr. Reddy’s Laboratories Company Details
11.9.2 Dr. Reddy’s Laboratories Business Overview
11.9.3 Dr. Reddy’s Laboratories Peptides Biosimilars Introduction
11.9.4 Dr. Reddy’s Laboratories Revenue in Peptides Biosimilars Business (2016-2021)
11.9.5 Dr. Reddy’s Laboratories Recent Development
11.10 Stada Arzneimittel AG
11.10.1 Stada Arzneimittel AG Company Details
11.10.2 Stada Arzneimittel AG Business Overview
11.10.3 Stada Arzneimittel AG Peptides Biosimilars Introduction
11.10.4 Stada Arzneimittel AG Revenue in Peptides Biosimilars Business (2016-2021)
11.10.5 Stada Arzneimittel AG Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Peptides Biosimilars Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Glucagon
Table 3. Key Players of Calcitonin
Table 4. Global Peptides Biosimilars Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Peptides Biosimilars Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Peptides Biosimilars Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Peptides Biosimilars Market Share by Regions (2016-2021)
Table 8. Global Peptides Biosimilars Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Peptides Biosimilars Market Share by Regions (2022-2027)
Table 10. Peptides Biosimilars Market Trends
Table 11. Peptides Biosimilars Market Drivers
Table 12. Peptides Biosimilars Market Challenges
Table 13. Peptides Biosimilars Market Restraints
Table 14. Global Peptides Biosimilars Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Peptides Biosimilars Market Share by Players (2016-2021)
Table 16. Global Top Peptides Biosimilars Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptides Biosimilars as of 2020)
Table 17. Ranking of Global Top Peptides Biosimilars Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Peptides Biosimilars Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Peptides Biosimilars Product Solution and Service
Table 21. Date of Enter into Peptides Biosimilars Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Peptides Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Peptides Biosimilars Revenue Market Share by Type (2016-2021)
Table 25. Global Peptides Biosimilars Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Peptides Biosimilars Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Peptides Biosimilars Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Peptides Biosimilars Revenue Market Share by Application (2016-2021)
Table 29. Global Peptides Biosimilars Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Peptides Biosimilars Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Peptides Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Peptides Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Peptides Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Peptides Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Peptides Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Peptides Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Peptides Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Peptides Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Peptides Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Peptides Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Peptides Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Peptides Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Peptides Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Peptides Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Peptides Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Peptides Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Peptides Biosimilars Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Peptides Biosimilars Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Peptides Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Peptides Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Peptides Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Peptides Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Peptides Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Peptides Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Peptides Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Peptides Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Peptides Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Peptides Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Peptides Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Peptides Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 61. Sandoz Company Details
Table 62. Sandoz Business Overview
Table 63. Sandoz Peptides Biosimilars Product
Table 64. Sandoz Revenue in Peptides Biosimilars Business (2016-2021) & (US$ Million)
Table 65. Sandoz Recent Development
Table 66. Pfizer Company Details
Table 67. Pfizer Business Overview
Table 68. Pfizer Peptides Biosimilars Product
Table 69. Pfizer Revenue in Peptides Biosimilars Business (2016-2021) & (US$ Million)
Table 70. Pfizer Recent Development
Table 71. Teva Pahrmaceutical Company Details
Table 72. Teva Pahrmaceutical Business Overview
Table 73. Teva Pahrmaceutical Peptides Biosimilars Product
Table 74. Teva Pahrmaceutical Revenue in Peptides Biosimilars Business (2016-2021) & (US$ Million)
Table 75. Teva Pahrmaceutical Recent Development
Table 76. Celltrion Company Details
Table 77. Celltrion Business Overview
Table 78. Celltrion Peptides Biosimilars Product
Table 79. Celltrion Revenue in Peptides Biosimilars Business (2016-2021) & (US$ Million)
Table 80. Celltrion Recent Development
Table 81. Biocon Company Details
Table 82. Biocon Business Overview
Table 83. Biocon Peptides Biosimilars Product
Table 84. Biocon Revenue in Peptides Biosimilars Business (2016-2021) & (US$ Million)
Table 85. Biocon Recent Development
Table 86. Amgen Company Details
Table 87. Amgen Business Overview
Table 88. Amgen Peptides Biosimilars Product
Table 89. Amgen Revenue in Peptides Biosimilars Business (2016-2021) & (US$ Million)
Table 90. Amgen Recent Development
Table 91. Samsung Biologics Company Details
Table 92. Samsung Biologics Business Overview
Table 93. Samsung Biologics Peptides Biosimilars Product
Table 94. Samsung Biologics Revenue in Peptides Biosimilars Business (2016-2021) & (US$ Million)
Table 95. Samsung Biologics Recent Development
Table 96. Mylan Company Details
Table 97. Mylan Business Overview
Table 98. Mylan Revenue in Peptides Biosimilars Business (2016-2021) & (US$ Million)
Table 99. Mylan Recent Development
Table 100. Dr. Reddy's Laboratories Company Details
Table 101. Dr. Reddy's Laboratories Business Overview
Table 102. Dr. Reddy's Laboratories Peptides Biosimilars Product
Table 103. Dr. Reddy's Laboratories Revenue in Peptides Biosimilars Business (2016-2021) & (US$ Million)
Table 104. Dr. Reddy's Laboratories Recent Development
Table 105. Stada Arzneimittel AG Company Details
Table 106. Stada Arzneimittel AG Business Overview
Table 107. Stada Arzneimittel AG Peptides Biosimilars Product
Table 108. Stada Arzneimittel AG Revenue in Peptides Biosimilars Business (2016-2021) & (US$ Million)
Table 109. Stada Arzneimittel AG Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptides Biosimilars Market Share by Type: 2020 VS 2027
Figure 2. Glucagon Features
Figure 3. Calcitonin Features
Figure 4. Global Peptides Biosimilars Market Share by Application: 2020 VS 2027
Figure 5. Oncology Case Studies
Figure 6. Chronic Diseases Case Studies
Figure 7. Autoimmune Diseases Case Studies
Figure 8. Blood Disorders Case Studies
Figure 9. Growth Hormone Deficiency Case Studies
Figure 10. Infectious Diseases Case Studies
Figure 11. Other Diseases Case Studies
Figure 12. Peptides Biosimilars Report Years Considered
Figure 13. Global Peptides Biosimilars Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Peptides Biosimilars Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Peptides Biosimilars Market Share by Regions: 2020 VS 2027
Figure 16. Global Peptides Biosimilars Market Share by Regions (2022-2027)
Figure 17. Global Peptides Biosimilars Market Share by Players in 2020
Figure 18. Global Top Peptides Biosimilars Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptides Biosimilars as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Peptides Biosimilars Revenue in 2020
Figure 20. Global Peptides Biosimilars Revenue Market Share by Type (2016-2021)
Figure 21. Global Peptides Biosimilars Revenue Market Share by Type (2022-2027)
Figure 22. North America Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Peptides Biosimilars Market Share by Type (2016-2027)
Figure 24. North America Peptides Biosimilars Market Share by Application (2016-2027)
Figure 25. North America Peptides Biosimilars Market Share by Country (2016-2027)
Figure 26. United States Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Peptides Biosimilars Market Share by Type (2016-2027)
Figure 30. Europe Peptides Biosimilars Market Share by Application (2016-2027)
Figure 31. Europe Peptides Biosimilars Market Share by Country (2016-2027)
Figure 32. Germany Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Peptides Biosimilars Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Peptides Biosimilars Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Peptides Biosimilars Market Share by Region (2016-2027)
Figure 42. China Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Peptides Biosimilars Market Share by Type (2016-2027)
Figure 50. Latin America Peptides Biosimilars Market Share by Application (2016-2027)
Figure 51. Latin America Peptides Biosimilars Market Share by Country (2016-2027)
Figure 52. Mexico Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Peptides Biosimilars Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Peptides Biosimilars Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Peptides Biosimilars Market Share by Country (2016-2027)
Figure 58. Turkey Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Peptides Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Sandoz Revenue Growth Rate in Peptides Biosimilars Business (2016-2021)
Figure 62. Pfizer Revenue Growth Rate in Peptides Biosimilars Business (2016-2021)
Figure 63. Teva Pahrmaceutical Revenue Growth Rate in Peptides Biosimilars Business (2016-2021)
Figure 64. Celltrion Revenue Growth Rate in Peptides Biosimilars Business (2016-2021)
Figure 65. Biocon Revenue Growth Rate in Peptides Biosimilars Business (2016-2021)
Figure 66. Amgen Revenue Growth Rate in Peptides Biosimilars Business (2016-2021)
Figure 67. Samsung Biologics Revenue Growth Rate in Peptides Biosimilars Business (2016-2021)
Figure 68. Mylan Revenue Growth Rate in Peptides Biosimilars Business (2016-2021)
Figure 69. Dr. Reddy's Laboratories Revenue Growth Rate in Peptides Biosimilars Business (2016-2021)
Figure 70. Stada Arzneimittel AG Revenue Growth Rate in Peptides Biosimilars Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

以下、関連資料のご紹介

世界のグリコシル化バイオシミラー市場規模・現状・予測（2021年-2027年）

Global Glycosylated Biosimilars Market Size, Status and Forecast 2021-2027
QYR2104Z2597 2021年4月 98Pages
QYResearch社発行の本調査資料では、グリコシル化バイオシミラーのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（mAb、EPO）、用途別市場規模（腫瘍、慢性疾患、自己免疫疾患、血液疾患、成長ホルモン欠乏症、感染症、その他）、主要地域別市場...

世界の内分泌ペプチド検査市場規模・現状・予測（2021年-2027年）

Global Endocrine Peptides Test Market Size, Status and Forecast 2021-2027
QYR2104Z2148 2021年4月 96Pages
QYResearch社発行の本調査資料では、内分泌ペプチド検査のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（エストラジオール（E2）、デヒドロエピアンドロステロン硫酸塩（DHEAS）、ヒト絨毛性ゴナドトロピン（hCG）、プロゲステロン、黄体形...

世界の内分泌ペプチド検査市場規模・現状・予測（2021年-2027年）

世界の組換え非グリコシル化タンパク質バイオシミラー市場規模・現状・予測（2021年-2027年）

Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size, Status and Forecast 2021-2027
QYR2104Z4957 2021年4月 90Pages
QYResearch社発行の本調査資料では、組換え非グリコシル化タンパク質バイオシミラーのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（インスリン、rHGH、インターフェロン）、用途別市場規模（腫瘍、慢性疾患、自己免疫疾患、血液疾患、成長ホルモ...

世界のバイオシミラー/フォローオンバイオロジクス市場規模・現状・予測（2021年-2027年）

Global Biosimilars/follow-on-biologics Market Size, Status and Forecast 2021-2027
QYR2104Z0847 2021年4月 92Pages
QYResearch社発行の本調査資料では、バイオシミラー/フォローオンバイオロジクスのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ヒト成長ホルモン、エリスロポエチン、モノクローナル抗体、インスリン、インターフェロン、顆粒球コロニー刺激因子、...

世界のバイオシミラー治療市場 2021：企業別、地域別、種類・用途別

Global Biosimilars Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z02251 2021年4月 103Pages
当調査資料では、バイオシミラー治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。バイオシミラー治療の種類別市場規模（組換え非グリコシル化タンパク質、組換えグリコシル化タンパク質、組換えペプチド）、用途別市場規模（腫瘍学、慢性・自己免疫疾患、血液疾患、...

世界の内皮機能障害市場規模・現状・予測（2021年-2027年）

Global Endothelial Dysfunction Market Size, Status and Forecast 2021-2027
QYR2104Z2164 2021年4月 92Pages
QYResearch社発行の本調査資料では、内皮機能障害のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（西洋医学治療、漢方治療）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、イン...

世界の合成ペプチド市場 2021：企業別、地域別、種類・用途別

Global Synthetic Peptides Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z13573 2021年4月 100Pages
当調査資料では、合成ペプチドのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。合成ペプチドの種類別市場規模（抗菌ペプチド、ベータアミロイドペプチド、細胞透過性ペプチド、アペリンペプチド）、用途別市場規模（製薬産業、研究所）、地域別市場規模（北米、アメリカ...

世界の網膜バイオシミラー市場 2021：企業別、地域別、種類・用途別

Global Retinal Biosimilars Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z11941 2021年4月 105Pages
当調査資料では、網膜バイオシミラーのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。網膜バイオシミラーの種類別市場規模（黄斑変性症薬、糖尿病性眼疾患薬、黄斑パッカー薬、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北米、...

世界の糖尿病網膜症治療市場規模・現状・予測（2021年-2027年）

Global Diabetic Retinopathy Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z1840 2021年4月 126Pages
QYResearch社発行の本調査資料では、糖尿病網膜症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（増殖性糖尿病性網膜症（PDR）、非増殖性糖尿病性網膜症（NPDR））、用途別市場規模（眼科クリニック、外来手術センター、病院、その他エン...

世界のグリコシル化バイオシミラー市場規模・現状・予測（2021年-2027年） Glycosylated Biosimilars include mA, EPO etc in this report. Market Analysis and Insights: Global Glycosylated Biosimilars Market The global Glycosylated Biosimilars market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industr…
世界の組換え非グリコシル化タンパク質バイオシミラー市場規模・現状・予測（2021年-2027年） Recombinant non-glycosylated proteins include human growth hormone, granulocyte colony-stimulating factor, interferons, and insulin. The statistic scope in this report is Recombinant non-glycosylated proteins biosimilars. Market Analysis and Insights: Global Recombinant Non-Glycosylated Proteins Bio…
世界の動物用自己免疫疾患検査市場規模・現状・予測（2021年-2027年） Animal autoimmune diseases are the result of specific immune responses and directed against self. Animals have the ability to control immune aggression. It acquired the capacity to avoid self-reaction called as tolerance, which allows removal of antigenic pathogens in the absence of self-recognition…
世界の動物用自己免疫疾患検査市場規模・現状・予測（2021年-2027年） Animal autoimmune diseases are the result of specific immune responses and directed against self. Animals have the ability to control immune aggression. It acquired the capacity to avoid self-reaction called as tolerance, which allows removal of antigenic pathogens in the absence of self-recognition…
世界のバイオシミラー/フォローオンバイオロジクス市場規模・現状・予測（2021年-2027年） Biosimilars or follow-on-biologics are the “copied” and licensed versions of those reference biologics that have undergone patent expiration. Biosimilars development and validation with reference biologics is a crucial aspect of the overall development process. Market Analysis and Insights: Global …